GUANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") $(POM)$, a leading online medical services platform for chronic diseases in China, today announced its unaudited financial results for the six months ended June 30, 2025.
Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "The first half of fiscal year 2025 reflected our deliberate and disciplined efforts to balance business expansion with operational rigor. Despite a challenging macroeconomic environment and intensified market competition, we strived to strengthen our market coverage and penetration, while optimizing and diversifying our revenue streams through the vigorous promotion of our internet-hospital services and online sales. During the period, we continued to solidify our partner-doctor pool by offering higher service fees, and at the same time meaningfully enhanced our collaboration with pharmaceutical manufacturers to drive online sales and adapt to China's evolving healthcare landscape. These initiatives resulted in a 16.2% increase in net revenue, highlighted by growth of 83.2% in our online-pharmacy businesses.
At the same time, we maintained strict cost controls and operational discipline, sustaining a stable gross profit margin of 16.2%. Gross profit increased 16.3% year over year, despite higher sales and marketing expenses, a larger contribution from lower-margin pharmacy products, and continued investments in customer acquisition. We prioritized retaining doctor resources while prudently reducing advertising spending, reinforcing the foundation for sustainable growth under a stable pharmaceutical supply chain.
Notably, our successful initial public offering (IPO) in October provided us with additional capital resources and expanded opportunities for future growth, further enriching our strategic options and strengthening our execution capabilities. Looking ahead, we are confident in our ability to continue improving operational performance and creating long-term value for our shareholders."
First Half of Fiscal 2025 Financial Summary
-- Net revenues for the six months ended June 30, 2025 were RMB174.5 million
(US$24.4 million), representing a 16.2% increase from RMB150.2 million in
the six months ended June 30, 2024.
-- Gross profit increased by 16.3% from RMB24.3 million in the six months
ended June 30, 2024, to RMB28.3 million (US$4.0 million) in the six
months ended June 30, 2025.
-- Gross profit margin remained stable at 16.2% in the six months ended June
30, 2024 and 2025.
-- Net loss was RMB19.9 million (US$2.8 million) for the six months ended
June 30, 2025, compared with RMB14.0 million for the six months ended
June 30, 2024.
-- Net loss per share, basic and diluted, was RMB11.45 (US$1.60) for the six
months ended June 30, 2025, compared with RMB10.58 for the six months
ended June 30, 2024.
Unaudited Financial Results for the First Half of Fiscal 2025
-- Net revenues for the six months ended June 30, 2025 were RMB174.5 million
(US$24.4 million), representing a 16.2% increase from RMB150.2 million in
the six months ended June 30, 2024, which was primarily attributable to
the increase in the net revenues from Internet hospital. Net revenues
from Internet hospital increased by 82.4% from RMB36.8 million in the six
months ended June 30, 2024 to RMB67.2 million (US$9.4 million) in the six
months ended June 30, 2025, primarily attributable to the increase in
revenues generated from online pharmacy sales. In the first half of 2025,
the Company strengthened its cooperation with pharmaceutical
manufacturers to sell their products through its Internet hospital
platform. As a result, revenue from the Company's online pharmacy sales
increased from RMB36.3 million in the six months ended June 30, 2024 to
RMB66.4 million (US$9.3 million) in the six months ended June 30, 2025.
-- Cost of revenues increased by 16.2% from RMB125.8 million in the six
months ended June 30, 2024 to RMB146.2 million (US$20.4 million) in the
six months ended June 30, 2025, primarily due to the increase in cost of
revenues in online pharmacy sales from RMB20.4 million in the six months
ended June 30, 2024 to RMB40.0 million (US$5.6 million) in the six months
ended June 30, 2025, which was in line with the increase in the Company's
net revenues from Internet hospital.
-- Gross profit increased by 16.3% from RMB24.3 million for the six months
ended June 30, 2024, to RMB28.3 million (US$4.0 million) in the six
months ended June 30, 2025.
-- Gross profit margin remained stable at 16.2% in the six months ended June
30, 2024 and 2025. The gross profit margin of the Company's Internet
hospital decreased from 44.7% in the six months ended June 30, 2024 to
40.5% in the six months ended June 30, 2025, mainly due to the increase
in the online pharmacy sales of products with lower gross profit margin.
The gross profit margin of the Company's pharmaceutical supply chain
business decreased from 6.9% in the six months ended June 30, 2024 to
1.1% in the six months ended June 30, 2025, which was primarily because
the gross profit margin of the Company's pharmacy wholesale customers
newly acquired in the six months ended June 30, 2024 was higher than that
of customers in the six months ended June 30, 2025.
-- Sales and marketing expenses increased by 11.6% from RMB24.9 million in
the six months ended June 30, 2024 to RMB27.8 million (US$3.9 million) in
the six months ended June 30, 2025, primarily due to higher service fees
to doctors and increased staff costs in line with the growth in revenues
from Internet hospital business, partially offset by a slight decrease in
advertising and promotion costs resulting from a relatively stable
pharmaceutical supply chain business.
-- General and administrative expenses increased by 53.5% from RMB6.8
million in the six months ended June 30, 2024 to RMB10.5 million (US$1.5
million) in the six months ended June 30, 2025, primarily due to the
increase in consultancy and professional service fees incurred in
connection with the Company's initial public offering, partially offset
by the decrease in expected credit loss recognized resulting from the
efforts for collection of receivables.
-- Research and development expense remained relatively stable at RMB1.5
million (US$0.2 million) for the six months ended June 30, 2024 and 2025.
-- Impairment loss on long-lived assets recorded was RMB0.02 million and
RMB2.0 million (US$0.3 million) for the six months ended June 30, 2024
and 2025, respectively.
-- Loss from operation was RMB13.5 million (US$1.9 million) for the six
months ended June 30, 2025, compared with RMB8.9 million for the six
months ended June 30, 2024.
-- Net loss was RMB19.9 million (US$2.8 million) for the six months ended
June 30, 2025, compared with RMB RMB14.0 million for the six months ended
June 30, 2024.
-- Net loss per share, basic and diluted, was RMB11.45 (US$1.60) for the six
months ended June 30, 2025, compared with RMB10.58 for the six months
ended June 30, 2024.
Financial Condition
-- Cash and cash equivalents of RMB5.7 million (US$0.8 million) as of June
30, 2025, compared to RMB7.7 million as of December 31, 2024.
-- Net cash used in operating activities was RMB15.0 million (US$2.1
million) for the six months ended June 30, 2025, compared with RMB10.6
million for the six months ended June 30, 2024.
-- Net cash used in investing activities was RMB512,200 (US$71,500) for the
six months ended June 30, 2025, compared with RMB17,862 for the six
months ended June 30, 2024.
-- Net cash provided by financing activities was RMB13.6 million (US$1.9
million) for the six months ended June 30, 2025, compared with RMB16.6
million for the six months ended June 30, 2024.
Exchange Rate Information
This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.1636 to US$1.00, the rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board on June 30, 2025.
Recent Development
On October 9, 2025, the Company completed its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. On October 10, 2025, the underwriter of the Offering fully exercised its over-allotment option to purchase an additional 750,000 American Depositary Shares of the Company at the public offering price of US$4.00 per share. The gross proceeds were US$23,000,016 from the Offering, before deducting underwriting discounts and commissions, and other expenses. The Company's ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker symbol "POM."
About POMDOCTOR LIMITED
POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
POMDOCTOR LIMITED
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
December 31, June 30, June 30,
2024 2025 2025
---------------- --------------- -------------
RMB RMB US$
---------------- --------------- -------------
Assets
Current assets:
Cash and cash
equivalents
(including amounts
of the consolidated
VIEs of
RMB7,596,708 and
RMB5,579,802
(US$778,910) as of
December 31, 2024
and June 30, 2025,
respectively) 7,651,695 5,746,989 802,249
Accounts receivable,
net (including
amounts of the
consolidated VIEs of
RMB8,374,608 and
RMB6,128,066
(US$855,445) as of
December 31, 2024
and June 30, 2025,
respectively) 8,374,608 6,128,066 855,445
Accounts receivable
-- a related party
(including amounts
of the
consolidated VIEs
of RMB424,259 and
RMB584,802
(US$81,635) as of
December 31, 2024
and June 30, 2025,
respectively) 424,259 584,802 81,635
Amount due from
related parties
(including amounts
of the consolidated
VIEs of
RMB6,070,945 and
RMB9,643,039
(US$1,346,117) as of
December 31, 2024
and June 30, 2025,
respectively) 5,632,987 7,418,671 1,035,607
Inventories
(including amounts
of the consolidated
VIEs of
RMB9,165,973 and
RMB6,447,637
(US$900,055) as of
December 31, 2024
and June 30, 2025,
respectively) 9,165,973 6,447,637 900,055
Other receivables,
net (including
amounts of the
consolidated VIEs of
RMB5,318,724 and
RMB5,231,722
(US$730,319) as of
December 31, 2024
and June 30, 2025,
respectively) 5,318,724 5,231,722 730,319
Advances to suppliers
(including amounts
of the consolidated
VIEs of RMB929,167
and RMB2,921,966
(US$407,891) as of
December 31, 2024
and June 30, 2025,
respectively) 929,167 2,921,966 407,891
--------------- --------------- -------------
Total current assets 37,497,413 34,479,853 4,813,201
--------------- --------------- -------------
Non-current assets:
Property and
equipment, net
(including amounts
of the consolidated
VIEs of RMB461,362
and RMB394,107
(US$55,015) as of
December 31, 2024
and June 30, 2025,
respectively) 461,362 394,107 55,015
Other non-current
assets (including
amounts of the
consolidated VIEs of
RMB831,132 and
RMB1,307,832
(US$182,566) as of
December 31, 2024
and June 30, 2025,
respectively) 831,132 1,307,832 182,566
Deferred offering
costs (including
amounts of the
consolidated VIEs of
RMB7,437,679 and
RMB6,007,339
(US$838,592) as of
December 31, 2024
and June 30, 2025,
respectively) 7,437,679 7,690,157 1,073,505
--------------- --------------- -------------
Total non-current
assets 8,730,173 9,392,096 1,311,086
--------------- --------------- -------------
Total assets 46,227,586 43,871,949 6,124,287
=============== =============== =============
POMDOCTOR LIMITED
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS -- (Continued)
December 31, June 30, June 30,
2024 2025 2025
---------------- --------------- -------------
RMB RMB US$
---------------- --------------- -------------
Liabilities
Current
liabilities:
Accounts payable
(including amounts
of the consolidated
VIEs of
RMB25,320,486 and
RMB25,164,804
(US$3,512,871) as of
December 31, 2024
and June 30, 2025,
respectively) 25,320,486 25,164,804 3,512,871
Accounts payable -- a
related party
(including amounts
of the consolidated
VIEs of RMB25,891
and RMB13,711
(US$1,914) as of
December 31, 2024
and June 30, 2025,
respectively) 25,891 13,711 1,914
Short-term bank loans
(including amounts
of the consolidated
VIEs of
RMB34,958,333 and
RMB34,708,333
(US$4,845,096) as of
December 31, 2024
and June 30, 2025,
respectively) 34,958,333 34,708,333 4,845,096
Long-term bank loans,
current (including
amounts of the
consolidated VIEs
of RMB300,000 and
RMB2,400,000
(US$335,027) as of
December 31, 2024
and June 30, 2025,
respectively) 300,000 2,400,000 335,027
Long-term loans,
current (including
amounts of the
consolidated VIEs of
RMB10,000,000 and
RMB10,000,000
(US$1,395,946) as of
December 31, 2024
and June 30, 2025,
respectively) 10,000,000 10,000,000 1,395,946
Long-term loans from
third parties,
current (including
amounts of the
consolidated VIEs
of RMB2,320,082 and
RMB2,295,082
(US$320,381) as of
December 31, 2024
and June 30, 2025,
respectively) 2,320,082 2,295,082 320,381
Salary and welfare
payable (including
amounts of the
consolidated VIEs
of RMB15,375,537
and RMB15,543,259
(US$2,169,755) as of
December 31, 2024
and June 30, 2025,
respectively) 15,375,537 15,543,259 2,169,755
Advance from
customers (including
amounts of the
consolidated VIEs of
RMB1,756,046 and
RMB942,724
(US$131,599) as of
December 31, 2024
and June 30, 2025,
respectively) 1,756,046 942,724 131,599
Value added tax
("VAT") and other
tax payable
(including amounts
of the
consolidated VIEs
of RMB815,462 and
RMB998,295
(US$139,357) as of
December 31, 2024
and June 30, 2025,
respectively) 815,462 998,295 139,357
Other payables
(including amounts
of the consolidated
VIEs of
RMB12,888,550 and
RMB10,543,238
(US$1,471,777) as of
December 31, 2024
and June 30, 2025,
respectively) 12,888,750 10,543,438 1,471,806
Accrued liabilities
(including amounts
of the consolidated
VIEs of
RMB9,712,966 and
RMB11,564,144
(US$1,614,292) as of
December 31, 2024
and June 30, 2025,
respectively) 9,712,966 11,564,144 1,614,292
Short-term loans from
third parties
(including amounts
of the consolidated
VIEs of
RMB11,551,614 and
RMB7,194,342
(US$1,004,291) as of
December 31, 2024
and June 30, 2025,
respectively) 11,551,614 7,194,342 1,004,291
Loans from related
parties, current
(including amounts
of the consolidated
VIEs of
RMB13,821,875 and
RMB33,194,670
(US$4,633,797) as of
December 31, 2024
and June 30, 2025,
respectively) 13,821,875 33,194,670 4,633,797
Amount due to related
parties (including
amounts of the
consolidated VIEs
of RMB36,829,010 and
RMB42,403,073
(US$5,919,241) as of
December 31, 2024
and June 30, 2025,
respectively) 36,829,010 42,403,073 5,919,241
POMDOCTOR LIMITED
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS -- (Continued)
December 31, June 30, June 30,
2024 2025 2025
---------------- --------------- -------------
RMB RMB US$
---------------- --------------- -------------
Operating lease
liabilities, current
(including amounts
of the
consolidated VIEs
of RMB1,388,863 and
RMB1,790,319
(US$249,919) as of
December 31, 2024
and June 30, 2025,
respectively) 1,388,863 1,790,319 249,919
Other current
liabilities
(including amounts
of the consolidated
VIEs of
RMB2,080,556 and
RMB237,580
(US$33,165) as of
December 31, 2024
and June 30, 2025,
respectively) 2,080,556 237,580 33,165
--------------- --------------- -------------
Total current
liabilities 179,145,471 198,993,774 27,778,457
--------------- --------------- -------------
Long-term bank loans,
noncurrent
(including amounts
of the
consolidated VIEs
of RMB8,400,000 and
RMB5,700,000
(US$795,689) as of
December 31, 2024
and June 30, 2025,
respectively) 8,400,000 5,700,000 795,689
Loans from related
parties, noncurrent
(including amounts
of the
consolidated VIEs
of RMB356,690,859
and RMB356,390,859
(US$49,750,246) as
of December 31, 2024
and June 30, 2025,
respectively) 356,690,859 356,390,859 49,750,246
Operating lease
liabilities,
noncurrent
(including amounts
of the
consolidated VIEs
of RMB1,672,218 and
RMB2,346,664
(US$327,582) as of
December 31, 2024
and June 30, 2025,
respectively) 1,672,218 2,346,664 327,582
--------------- --------------- -------------
Total non-current
liabilities 366,763,077 364,437,523 50,873,517
--------------- --------------- -------------
Total liabilities 545,908,548 563,431,297 78,651,974
=============== =============== =============
Commitments and
contingencies -- -- --
Mezzanine equity
Convertible
redeemable preferred
shares (US$0.0001
par value;
12,597,228 shares
authorized, issued
and outstanding as
of December 31,
2024 and June 30,
2025) 1,595,051,558 1,642,498,390 229,283,934
Redeemable
non-controlling
interests 168,671,234 173,630,137 24,237,833
--------------- --------------- -------------
Total mezzanine
equity 1,763,722,792 1,816,128,527 253,521,767
Equity (deficit)
Class A ordinary
shares (US$0.0001
par value;
485,360,730 shares
authorized,
4,268,156 shares
issued and
outstanding as of
December 31, 2024
and June 30, 2025) 2,988 2,988 417
Class B Ordinary
shares (US$0.0001
par value; 2,042,042
shares authorized
and outstanding as
of December 31, 2024
and June 30, 2025,
respectively) 1,408 1,408 197
Subscription
receivable (1,608) (1,608) (224)
Accumulated deficit (2,263,419,477) (2,335,709,744) (326,052,508)
Accumulated other
comprehensive (loss)
income (5,231) 1,875 262
--------------- --------------- -------------
Total Pomdoctor
Limited's
shareholders'
deficit (2,263,421,920) (2,335,705,081) (326,051,856)
--------------- --------------- -------------
Noncontrolling
interests 18,166 17,206 2,402
--------------- --------------- -------------
Total deficit (2,263,403,754) (2,335,687,875) (326,049,454)
--------------- --------------- -------------
Total liabilities,
mezzanine equity and
deficit 46,227,586 43,871,949 6,124,287
=============== =============== =============
POMDOCTOR LIMITED
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS
For Six Months Ended June 30,
-----------------------------------------
2024 2025 2025
------------- ------------ ------------
RMB RMB US$
------------- ------------ ------------
Net
revenues -- third
parties 149,266,587 174,283,295 24,329,010
Net revenues -- a
related party 897,822 186,556 26,042
------------ ------------ ------------
Net revenues 150,164,409 174,469,851 24,355,052
Cost of revenues 125,823,734 146,152,450 20,402,095
------------ ------------ ------------
Gross profit 24,340,675 28,317,401 3,952,957
Operating
expenses:
Sales and marketing
expenses 24,884,898 27,761,736 3,875,389
General and
administrative
expenses 6,835,897 10,494,487 1,464,974
Research and
development
expenses 1,507,847 1,479,909 206,587
Impairment loss on
long-lived assets 17,861 2,041,299 284,954
------------ ------------ ------------
Total operating
expenses 33,246,503 41,777,431 5,831,904
------------ ------------ ------------
Loss from operations (8,905,828) (13,460,030) (1,878,947)
Other income
(expenses):
Other income 1,078,270 28,027 3,912
Other expense (33,681) (130,291) (18,188)
Interest expense (6,179,172) (6,471,198) (903,344)
Government grants 13,858 148,000 20,660
------------ ------------ ------------
Total other expense,
net (5,120,725) (6,425,462) (896,960)
Loss before income
tax (14,026,553) (19,885,492) (2,775,907)
Income tax expense -- -- --
------------ ------------ ------------
Net loss (14,026,553) (19,885,492) (2,775,907)
Accretion to
redemption value of
mezzanine equity (52,695,272) (52,405,735) (7,315,559)
Less: Net income
(loss) attributable
to noncontrolling
interests 27,639 (960) (134)
------------ ------------ ------------
Net loss
attributable to the
Pomdoctor Limited's
ordinary
shareholders (66,749,464) (72,290,267) (10,091,332)
Net loss (14,026,553) (19,885,492) (2,775,907)
Other
comprehensive
(loss) income:
Total other
comprehensive
(loss) income (3,970) 7,106 992
------------ ------------ ------------
Total comprehensive
loss (14,030,523) (19,878,386) (2,774,915)
------------ ------------ ------------
Accretion to
redemption value of
mezzanine equity (52,695,272) (52,405,735) (7,315,559)
Less: comprehensive
income (loss)
attributable to
noncontrolling
interests 27,639 (960) (134)
------------ ------------ ------------
Comprehensive loss
attributable to the
Pomdoctor Limited's
ordinary
shareholders (66,753,434) (72,283,161) (10,090,340)
============ ============ ============
Loss per share
Basic and diluted (10.58) (11.45) (1.60)
============ ============ ============
Weighted average
number of ordinary
shares
outstanding*
Basic and diluted 6,310,198 6,310,198 6,310,198
============ ============ ============
* Ordinary shares and share data have been retroactively
restated to give effect to the nominal share issuance for
the Reorganization completed on August 8, 2024
POMDOCTOR LIMITED
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For Six Months Ended June 30,
----------------------------------------
2024 2025 2025
------------- ------------ -----------
RMB RMB US$
------------- ------------ -----------
Net cash used in
operating
activities (10,631,121) (14,987,658) (2,092,195)
------------ ------------ -----------
Cash flows from
investing
activities:
Payment for
purchase of
property and
equipment (17,862) (2,200) (307)
Payment for
long-term
investment -- (510,000) (71,193)
------------ ------------ -----------
Net cash used in
investing
activities (17,862) (512,200) (71,500)
------------ ------------ -----------
Cash flows from
financing
activities:
Loans from related
parties 11,219,986 24,750,310 3,455,010
Repayment to
related parties (14,436,941) (5,677,514) (792,550)
Proceeds from
short-term bank
loans 37,000,000 29,000,000 4,048,244
Repayment of
short-term bank
loans (19,300,000) (29,250,000) (4,083,143)
Repayment of
long-term bank
loans (54,628) (600,000) (83,757)
Loans from third
parties 8,759,366 1,600,000 223,351
Repayment to third
parties (4,968,912) (5,982,272) (835,093)
Payment for
deferred offering
cost (1,656,745) (252,478) (35,245)
------------ ------------ -----------
Net cash provided
by financing
activities 16,562,126 13,588,046 1,896,817
------------ ------------ -----------
Effect of exchange
rate changes (3,970) 7,106 992
------------ ------------ -----------
Net increase
(decrease) in cash
and cash
equivalents and
restricted cash 5,909,173 (1,904,706) (265,886)
Cash and cash
equivalents and
restricted cash at
beginning of the
period 6,805,099 7,651,695 1,068,135
------------ ------------ -----------
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS -- (Continued)
For Six Months Ended June 30,
----------------------------------------
2024 2025 2025
------------- ------------ -----------
RMB RMB US$
------------- ------------ -----------
Including:
Cash and cash
equivalents at
beginning of
the period 6,717,031 7,651,695 1,068,135
Restricted
cash at
beginning of
the period 88,068 -- --
Cash and cash
equivalents and
restricted cash at
end of the period 12,714,272 5,746,989 802,249
------------ ------------ -----------
Including:
Cash and cash
equivalents at
end of the
period 12,714,272 5,746,989 802,249
Supplemental
disclosures of
cash flows
information:
Cash paid for
interest expense 1,130,609 2,382,125 332,532
Supplemental
disclosure of
noncash investing
and financing
activities:
Operating lease
right-of-use
assets obtained in
exchange for new
operating lease
liabilities -- 2,039,099 284,647
View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-first-half-of-fiscal-2025-unaudited-financial-results-302632067.html
SOURCE POMDOCTOR LIMITED
(END) Dow Jones Newswires
December 03, 2025 16:15 ET (21:15 GMT)
Comments